FEWER than a quarter of patients with systemic lupus erythematosus (SLE) achieve a major clinical response (MCR) after treatment escalation, with Black patients showing a lower observed response than White patients, a new study has shown.
Systemic Lupus Erythematosus and Ethnicity
Ethnic disparities in SLE outcomes are well documented, but data on treatment response across ethnic groups remained scarce. This study therefore evaluated the effect of ethnicity on clinical outcomes following treatment escalation in a diverse UK cohort of patients with systemic lupus erythematosus.
How Was Response Measured?
This longitudinal cohort study analysed data from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR), which recruited patients from 64 UK secondary and tertiary rheumatology and nephrology centres between 1 July 2010 and 10 November 2021.
Eligible patients were aged 16 years and older with active moderate-to-severe SLE (at least one BILAG A score, at least two BILAG B scores, or a SLEDAI-2K score of at least 6) and had initiated rituximab or belimumab within the past 12 months, or standard immunosuppressive therapy within the past 1 month.
Ethnicity was categorized as White, South Asian, Black, East Asian, or mixed or other ethnicities. Of 1,688 patients recruited, 1,266 did not meet the eligibility criteria, leaving 422 patients, of whom 383 (91%) were female, 39 (9%) were male, and median age was 40.5 years.
Responses Differ By Ethnicity
At baseline, Black patients had higher disease activity, greater organ damage, and more comorbidities.
At 12 months, 99 (23%) of 422 patients had met MCR criteria, including 42% of 19 East Asian patients, 30% of 77 South Asian patients, 24% of 245 White patients, 10% of 70 Black patients, and 9% of 11 patients with mixed or other ethnicities.
Notably, in the adjusted five-group model, patients of Black ethnicity had lower odds of meeting MCR criteria than White patients (odds ratio: 0.13).
Towards More Equitable Lupus Care
MCR criteria were met by fewer than a quarter of patients after treatment escalation, and patients of Black ethnicity have shown higher baseline disease burden and lower observed response than White patients.
These results support the need for more personalised, equitable approaches to systemic lupus erythematosus management and reinforce the importance of ensuring diversity in clinical research.
Reference
Dyball S et al. Effect of ethnicity on response to treatment escalation in patients with systemic lupus erythematosus from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a longitudinal cohort study. Lancet Rheumatol. 2026;DOI:10.1016/S2665-9913(26)00223-7.